Italia markets open in 1 hour 21 minutes

Biophytis S.A. (0D1W.L)

LSE - LSE Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
2,9700+2,8625 (+2.662,79%)
Alla chiusura: 03:42PM BST
Schermo intero
Chiusura precedente0,1075
Aperto0,1049
Denaro0,0000 x N/D
Lettera0,0000 x N/D
Min-Max giorno0,1041 - 0,1060
Intervallo di 52 settimane0,1041 - 0,1060
Volume2.523
Media VolumeN/D
CapitalizzazioneN/D
Beta (5 anni mensile)1,42
Rapporto PE (ttm)N/D
EPS (ttm)-0,2640
Prossima data utiliN/D
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Biophytis to Restate Previously Issued Financial Statements

    PARIS and CAMBRIDGE, Mass., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS) (the “Company” or “Biophytis”), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, today announced that the Company’s previously iss

  • GlobeNewswire

    Biophytis to Host Virtual KOL Event on Sarconeos (BIO101) on its Lead Projects in COVID-19 and Sarcopenia

    PARIS and CAMBRIDGE, Mass., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, today announces it will host a virtual key opinion leader (KOL) event on October

  • GlobeNewswire

    Biophytis Announces the Drawing of 2 New Tranches of ORNANE Under the 2020 Atlas Contract for €6 Million

    PARIS and CAMBRIDGE, Mass., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, today announces the issuance of 240 Bonds Redeemable in Cash and New and Exist